Endonovo Therapeutics, Inc. (ENDV) stock
Close on Oct 19, 2026Market cap $135.08KP/E –Yield –
Endonovo Therapeutics, Inc. grew revenue 1699.9% to $255.72K over the twelve months to Sep 30, 2023. At the latest close the market valued the company at $135.08K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2023
Valuation
- Market cap
- $135.08K
- P/E ratio
- –
- Price to sales
- 0.53
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $255.72K
- Net income
- -$4.40M
- EPS, diluted
- -$0.08
- Book value per share
- -$0.02
- Diluted shares
- 1.35B
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 200,000
- Average volume (20 days)
- 451,067
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ENDV | S&P 500 | Difference | ENDV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | 0.0% | +3.4% | −3.4 pts | ||
| Year to date | 0.0% | +13.3% | −13.3 pts | ||
| 1 year | 0.0% | +16.6% | −16.6 pts | ||
| 3 years | -99.3% | +86.4% | −185.7 pts | -80.7% | +23.1% |
| 5 years | -99.6% | +81.9% | −181.5 pts | -66.9% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.9 pts | -75.3% | +15.4% |
Fourteen years at a glance
Fiscal years 2009 to 2022 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Endonovo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
About Endonovo Therapeutics
Electromedical & Electrotherapeutic Apparatus
Endonovo Therapeutics, Inc. is a biotechnology company that creates bioelectronic medical devices for regenerative medicine and post-operative care. Its primary product is SofPulse, a wearable, non-invasive therapeutic device using pulsed electro-magnetic fields to stimulate cellular recovery, accelerate wound healing, and alleviate post-surgical pain and inflammation. The company also investigates bioelectric treatments targeting cardiovascular diseases, chronic kidney disease, and central nervous system disorders. Additionally, it operates a telehealth platform designed to distribute non-opioid pain reduction therapies directly to consumers, and provides commercial medical devices to medical care providers.
Company profile, executives and historyEndonovo Therapeutics stock: common questions
What is Endonovo Therapeutics's stock price?
ENDV closed at $0.00 on Oct 19, 2026, up 0.00% on the day.
What is Endonovo Therapeutics's market cap?
Endonovo Therapeutics was worth $135.08K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ENDV's P/E ratio?
Endonovo Therapeutics lost money over the twelve months to Sep 30, 2023 (diluted EPS -$0.08), so it has no meaningful P/E ratio.
How much revenue does Endonovo Therapeutics make?
Endonovo Therapeutics reported revenue of $255.72K for the twelve months to Sep 30, 2023, up 1699.9% from a year earlier.
Does Endonovo Therapeutics pay a dividend?
No. Endonovo Therapeutics has not paid a cash dividend over the last twelve months.
How has ENDV stock performed over the past year?
Including dividends, ENDV returned 0.0% over the past year, against +16.6% for the S&P 500.
Who are Endonovo Therapeutics's competitors?
Companies most similar to Endonovo Therapeutics by business, industry and size include ECOR, AXGN, FOCL, NXL, LIVN.
See a number that looks wrong?